Results 71 to 80 of about 1,335,871 (234)

CEA, CYFRA 21-1, NSE, and ProGRP in the diagnosis of lung cancer: a multivariate approach [PDF]

open access: yes, 2008
We retrospectively studied the single and combined diagnostic value of carcinoembryonic antigen (CEA), cytokeratin fragment 19 (CYFRA 21-1), neuron specific enolase (NSE) and pro-gastrin-releasing peptide (ProGRP), which were routinely analysed in ...
Barak   +21 more
core   +1 more source

Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer

open access: yesNew England Journal of Medicine, 2017
Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK‐positive non–small‐cell lung cancer (NSCLC).
S. Peters   +16 more
semanticscholar   +1 more source

HBXIP suppression reduces cell proliferation and migration and its overexpression predicts poor prognosis in non-small-cell lung cancer

open access: yesTumor Biology, 2017
Emerging evidence has demonstrated that the high expression of HBXIP has been correlated with many cancers. With evaluation of the functional role of HBXIP in non-small-cell lung cancer, the primary aim of this study is to investigate the correlation ...
Yixuan Wang   +6 more
doaj   +1 more source

MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. [PDF]

open access: yes, 2019
Lung cancer remains the most lethal cancer among men and women in the United States and worldwide. The majority of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Developing new therapeutics on the basis of better understanding of
Petrek, Hannah, Yu, Ai-Ming
core   +1 more source

Afatinib treatment in advanced non-small cell lung cancer

open access: yesLung Cancer: Targets and Therapy, 2011
Jane L Hurwitz, Paula Scullin, Lynn CampbellDepartment of Medical Oncology, Northern Ireland Cancer Centre, Belfast, UKAbstract: Despite some recent advances in the management of advanced non-small cell lung cancer (NSCLC), prognosis for these patients ...
Hurwitz JL, Scullin P, Campbell L
doaj  

Immunotherapy in inoperable stage III non-small cell lung cancer: a review

open access: yesDrugs in Context, 2019
The leading cause of cancer-related deaths in the United States continues to be lung cancer. Approximately 25–30% of patients are diagnosed with locally advanced nonsmall cell lung cancer (NSCLC).
Natasha A Jain, Gregory A Otterson
doaj   +1 more source

Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872 [PDF]

open access: yes, 1991
A total of 62 patients with metastatic or locally advanced non-small-cell lung cancer were entered in a phase II study of ACNU. Initially, the drug was given i. v.
Ardizzoni, A. (A.)   +8 more
core   +2 more sources

MET Inhibition in Non-Small Cell Lung Cancer

open access: yesEuropean Medical Journal, 2019
Cancer treatment paradigms have evolved over recent years with an emphasis on personalised medicine. Targeted agents are being used to improve treatment outcomes and quality of life.
Shabnam Rehman, Grace K. Dy
doaj  

Long noncoding nature brain-derived neurotrophic factor antisense is associated with poor prognosis and functional regulation in non–small cell lung caner

open access: yesTumor Biology, 2017
In this study, we evaluated the prognostic potential and functional regulation of human nature antisense, brain-derived neurotrophic factor antisense, in non–small cell lung cancer.
MingJing Shen   +5 more
doaj   +1 more source

Curcumin increases the sensitivity of Paclitaxel-resistant NSCLC cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction

open access: yesTumor Biology, 2017
Non-small-cell lung cancer is one of the most lethal cancers in the worldwide. Although Paclitaxel-based combinational therapies have long been used as a standard treatment in aggressive non-small-cell lung cancers, Paclitaxel resistance emerges as a ...
Yimin Lu   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy